ECS Botanics Holdings (ASX:ECS) is set to supply its Avani THC10 soft gel capsules to support an upcoming investigator-led clinical trial by the Center for Sleep Science at the University of Western Australia, to assess the therapeutic potential of medicinal cannabis in patients with clinically-significant obstructive sleep apnea, according to a Monday Australian bourse filing.
It will examine the impact of 10 milligrams of tetrahydrocannabinol on obstructive sleep apnea severity and contributing physiological mechanisms, along with psychomotor and cognitive outcomes.
The trial targets the enrollment of 24 participants and is expected to open within the year. Recruitment is expected to begin in July.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。